News
![ASCO 2024](/sites/default/files/styles/x_large/public/2024-05/ASCO.jpg?itok=0vr9QTGo)
ASCO: Merus bispecific garners attention after abstract drop
Among the myriad of new studies highlighted in the newly published ASCO abstracts, Merus’ seems to have struck a chord with its phase 2 trial of bispecific antibody petose